XORTX Therapeutics Inc. (XRTX) Quality Score
Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.
Broad-market heuristics · Not a buy/sell signal
Valuation and growth
Valuation
Growth
Negative earnings, no valuation support
Negative FCF, no valuation support
FCF negative, burning cash after capex
Business Quality & Capital Allocation
Heavy dilution above 5%
Net cash position, no leverage concern
Below 8%, may not cover cost of capital
XORTX Therapeutics (XRTX) quality: score, margins and returns
XORTX Therapeutics (XRTX) scores 10/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 4 metrics each scored 0 to 100 and -93.6% ROIC. Every metric is computed from company filings; this is analysis, not investment advice.
Frequently asked
Is XORTX Therapeutics (XRTX) a high-quality business?+
XORTX Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Recent figures include a -93.6% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.
What does XORTX Therapeutics's quality score measure?+
Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from XRTX's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where XORTX Therapeutics scores well and where it falls behind.
What is XORTX Therapeutics's return on invested capital (ROIC)?+
XORTX Therapeutics earns about -93.6% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to XRTX's margins and growth on this scorecard to judge durability.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.